DorsaVi Ltd (ASX: DVL) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
DorsaVi Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$7.37 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
669.78 million
Earnings per share
-0.003
Dividend per share
N/A
Year To Date Return
-8.33%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
DorsaVi Ltd (ASX: DVL)
Latest News
Share Market News
Why the Dorsavi (ASX:DVL) share price is flying 22% higher today
Share Market News
Why the Dorsavi share price rocketed 277% higher yesterday
⏸️ Investing
Why these 4 ASX shares have tumbled lower today
⏸️ Investing
Dorsavi Ltd share price jumps 8% on FDA clearance
⏸️ Investing
The Dorsavi Ltd share price just fell 16% to a 52-week low
⏸️ Investing
Why these 4 ASX shares have sunk like stones today
⏸️ Investing
3 speculative micro-cap shares that could make you a fortune
⏸️ Investing
Why tech share Dorsavi Ltd surged higher today
⏸️ Investing
ASX 200 soars: 13 shares you should have been watching
⏸️ Investing
Why Dorsavi Ltd is one of 5 shares SINKING today
⏸️ Investing
5 explosive growth shares I will be watching in 2017
⏸️ Investing
5 shares under $5 with massive growth potential
1❯
DVL ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About DorsaVi Ltd
DorsaVi Ltd is engaged in the development and sale of motion analysis technologies. Its technologies are commercialized via license, sale, or fixed-fee consultancy. The company makes wearable sensors, software, and sophisticated algorithmsthat measure movement and muscle activation at around 200 frames per second. The company's products include ViSafe (Workplace), ViMove (Clinic), and others. The firm operates in two reportable segments: Clinical, and Workplace. A majority of its revenue is generated from the Clinical segment. Geographically, the company derives maximum revenue from the United States of America, and the rest from Australia, and Europe.
DVL Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 04 Nov 2024 | $0.01 | $0.00 | 0.00% | 5,000 | $0.01 | $0.01 | $0.01 |
| 31 Oct 2024 | $0.01 | $0.00 | 0.00% | 2,362,000 | $0.01 | $0.01 | $0.01 |
| 29 Oct 2024 | $0.01 | $0.00 | 0.00% | 1,000,000 | $0.01 | $0.01 | $0.01 |
| 28 Oct 2024 | $0.01 | $0.00 | 0.00% | 57,454 | $0.01 | $0.01 | $0.01 |
| 25 Oct 2024 | $0.01 | $0.00 | 0.00% | 512,835 | $0.01 | $0.01 | $0.01 |
| 22 Oct 2024 | $0.01 | $0.00 | 0.00% | 100,000 | $0.01 | $0.01 | $0.01 |
| 21 Oct 2024 | $0.01 | $0.00 | 0.00% | 199,933 | $0.01 | $0.01 | $0.01 |
| 18 Oct 2024 | $0.01 | $0.00 | 0.00% | 30,752 | $0.01 | $0.01 | $0.01 |
| 17 Oct 2024 | $0.01 | $0.00 | 0.00% | 100,381 | $0.01 | $0.01 | $0.01 |
| 16 Oct 2024 | $0.01 | $0.00 | 0.00% | 156,590 | $0.01 | $0.01 | $0.01 |
| 15 Oct 2024 | $0.01 | $0.00 | 0.00% | 1,211,615 | $0.01 | $0.01 | $0.01 |
| 10 Oct 2024 | $0.01 | $0.00 | 0.00% | 40,207 | $0.01 | $0.01 | $0.01 |
| 09 Oct 2024 | $0.01 | $0.00 | 0.00% | 1,145,000 | $0.01 | $0.01 | $0.01 |
| 08 Oct 2024 | $0.01 | $0.00 | 0.00% | 534,200 | $0.01 | $0.01 | $0.01 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 13 Jun 2024 | Andrew Ronchi | Issued | 1,100,000 | $13,200 |
Issue of securities.
|
| 13 Jun 2024 | Andrew Ronchi | Issued | 1,000,000 | $12,000 |
Issue of securities. 1,000,000 Performance Rights
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Gernot Kurt Abl | Non-Executive DirectorNon-Executive Chairman | Mar 2024 |
Mr Abl is a public company director with a background in law, corporate finance, and management consulting and has more than 20 years of entrepreneurial, business strategy, and investment experience. Gernot has worked with many early-stage businesses, across industries, to help commercialise, grow, and increase the value of the business for all stakeholders. Gernot is also on the board of and advises several medium and high-growth businesses, ranging from early-stage pre-revenue companies through to early-stage ASX-listed companies.
|
| Dr Andrew James Ronchi | Chief Executive OfficerExecutive Director | Feb 2008 |
Mr Ronchi was a practicing physiotherapist both at an AFL club and in private practice. He has also been founding partner in two physiotherapy centers, the largest of these employing 28 staff (including 13 physiotherapists).
|
| Dr Michael Winlo | Non-Executive Director | Oct 2023 |
Dr Winlo has a leadership experience across the biotechnology, pharmaceutical and technology sectors. He is currently Chief Executive Officer. Dr Winlo also serves as a director and former CEO of Linear Clinical Research, a world-class provider of early and late-stage pharmaceutical trial facilities and management services. Prior to his role at Linear, Dr Winlo was based in Silicon Valley for five years as the Health Lead at Palantir Technologies (NYSE: PLTR).
|
| Mr Vineet Agarwal | Non-Executive Director | Sep 2024 |
Mr Agarwal has 18 years in the technology sector. Mr Agarwal is currently Product Management Director at Advanced Micro Devices (NASDAQ:AMD), where he has overseen management and product launch of the Ryzen Client Product line. Prior to AMD, Mr Agarwal held strategic roles at Qualcomm (NASDAQ:QCOM), including Director of Program Management and Senior Manager, driving the development of QCOMs Snapdragon platform.
|
| Mr Justin Mouchacca | Company Secretary | Sep 2023 |
-
|
| Justin Mouchacca | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Mr Bilal Ahmad | 53,500,000 | 7.99% |
| Mrs Ifrah Nishat | 50,027,271 | 7.48% |
| Starfish Technology Fund II Nominees A Pty Ltd | 48,763,230 | 7.29% |
| Starfish Technology Fund II Nominees B Pty Ltd | 48,763,229 | 7.29% |
| Miss Ifrah Nishat | 40,034,955 | 5.98% |
| Vesparum Group Investments Pty Ltd | 23,511,311 | 3.51% |
| Ms Chunyan Niu | 23,455,438 | 3.51% |
| Mr Bin Liu | 17,958,568 | 2.68% |
| David Dominic Pevcic | 16,545,454 | 2.47% |
| Kobala Investments Pty Ltd Fernando Edward Family A/C | 16,409,090 | 2.45% |
| Valence Holdings Pty Ltd the PW & CM Stinton Superannuation Fund A/C | 15,277,779 | 2.28% |
| Tanarny Super Fund Pty Ltd Tanarny Super Fund A/C | 14,209,132 | 2.12% |
| Ddpevcic (WA) Pty Ltd (Dominic Family A/C) | 12,590,909 | 1.88% |
| Hall Capital Finance Pty Ltd Phoenix Microcap A/C | 11,916,942 | 1.78% |
| 449 Investments Pty ltd the A&R Hynes Family S/F A/C | 9,791,667 | 1.46% |
| AR BSM Pty Ltd AR BSM A/C | 8,706,965 | 1.30% |
| Dr Zonair Ikram | 8,352,903 | 1.25% |
| Mr Salvatore Di Vincenzo | 8,087,189 | 1.21% |
| Mr Dean Brett Blankfield Dean Blankfield A/C | 6,636,363 | 0.99% |
| Creative Hindsight Pty Ltd | 6,360,871 | 0.95% |
